Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 771-780

  Neuman, Brian P ^e   Eifler, John B ^c   Castanares, Mark ^d   Chowdhury, Wasim H ^e   Chen, Ying ^b   Mease, Ronnie C ^b   Ma, Rong ^a   Mukherjee, Amarnath ^a   Lupold, Shawn E ^a   Pomper, Martin G ^b   Rodriguez, Ronald ^e,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e University of Texas Health Science Center   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; INDOCYANINE GREEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; YC 27; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSISTIVE TECHNOLOGY DEVICE; CAMERA; CANCER RECURRENCE; CANCER SURGERY; CLINICAL EFFECTIVENESS; DRUG CLEARANCE; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING SYSTEM; LAPAROSCOPE; LAPAROSCOPIC SURGERY; MALE; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PROSTATE CANCER; ROBOTICS; VALIDITY; ANIMAL; DIAGNOSTIC IMAGING; DISEASE MODEL; INFRARED SPECTROPHOTOMETRY; LAPAROSCOPY; PIG; PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS; XENOGRAFT;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; FLUORESCENT DYES; HETEROGRAFTS; LAPAROSCOPY; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SPECTROPHOTOMETRY, INFRARED; SWINE;

EID: 84923164097     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0891     Document Type: Article

References (35)

1. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: The 30-year anniversary. J Urol 2012;188:2219-24.
2. Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55: 87-99.
3. Tsuboi T, Ohori M, Kuroiwa K, Reuter VE, Kattan MW, Eastham JA, et al. Is intraoperative frozen section analysis an efficient way to reduce positive surgical margins? Urology 2005;66:1287-91.
4. Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, et al. Impact of surgical margin status on prostate-cancer-specific mortality. BJU Int 2012;110:1684-9.
5. Van-der-Kwast TH, Bolla M, Van-Poppel H, Van-Cangh P, Vekemans K, Da-Pozzo L, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25:4178-86.
6. Showalter TN, Foley KA, Jutkowitz E, Lallas CD, Trabulsi EJ, Gomella LG, et al. Costs of early adjuvant radiation therapy after radical prostatectomy: A decision analysis. Ann Oncol 2012;23:701-6.
7. Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes ofminimally invasive radical prostatectomy. J Clin Oncol 2008;26: 2278-84.
8. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001;19:316-7.
9. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011;71:281-8.
10. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specificmembrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
11. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009;40: 1754-61.
12. Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, et al. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl 2011;50:9167-70.
13. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey- Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012;53:1883-91.
14. Hrkach J, Von-Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:128ra139.
15. Laydner H, Huang SS, Heston WD, Autorino R, Wang X, Harsch KM, et al. Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: A feasibility study. Urology 2013;81: 451-6.
16. Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011;121:2383-90.
17. Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009;390:624-9.
18. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.
19. Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostatespecific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001;12:117-23.
20. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostatespecific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
21. Rovenska M, Hlouchova K, Sacha P, Mlcochova P, Horak V, Zamecnik J, et al. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate 2008;68:171-82.
22. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61.
23. FDA. Guidance for industry, investigators, and reviewers exploratory IND studies. In: Office of Training and Communication DoDI, HFD-240, Center for Drug Evaluation and Research, editor. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2006. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf.
24. Treuting PM, Chen LI, Buetow BS, Zeng W, Birkebak TA, Seewaldt VL, et al. Retinoic acid receptor beta2 inhibition of metastasis in mouse mammary gland xenografts. Breast Cancer Res Treat 2002;72: 79-88.
25. Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001;19:327-31.
26. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 2009;8:505-6.
27. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011;17:1315-9.
28. Helland O, Popa M, Vintermyr OK, Molven A, Gjertsen BT, Bjorge L, et al. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS ONE 2014;9:e89527.
29. Verbeek FP, van der Vorst JR, Tummers QR, Boonstra MC, de Rooij KE, Lowik CW, et al. Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. Ann Surg Oncol 2014;Suppl 4:528-37.
30. Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, et al. The FLARE intraoperative near-infrared fluorescence imaging system: A first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009;16:2943-52.
31. Ito A, Ito Y, Matsushima S, Tsuchida D, Ogasawara M, Hasegawa J, et al. New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice. Gastric Cancer 2014;17:497-507.
32. Heath CH, Deep NL, Beck LN, Day KE, Sweeny L, Zinn KR, et al. Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice. Otolaryngol Head Neck Surg 2013;148:982-90.
33. Ishizawa T, Fukushima N, Shibahara J, Masuda K, Tamura S, Aoki T, et al. Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer 2009;115:2491-504.
34. Eckelman WC, Reba RC, Gibson RE, Rzeszotarski WJ, Vieras F, Mazaitis JK, et al. Receptor-binding radiotracers: A class of potential radiopharmaceuticals. J Nucl Med 1979;20:350-7.
35. Tobis S, Knopf J, Silvers C, Yao J, Rashid H, Wu G, et al. Near infrared fluorescence imaging with robotic assisted laparoscopic partial nephrectomy: initial clinical experience for renal cortical tumors. J Urol 2011; 186:47-52.